Pablo L Ortiz-Romero

List of Publications by Citations

120 papers	4,507 citations	30 h-index	66 g-index
129 ext. papers	5,537 ext. citations	5.1 avg, IF	4.54 L-index

#	Paper	IF	Citations
120	Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. *Blood*, **2008**, 111, 838-45	2.2	492
119	Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. *Journal of Clinical Oncology*, **2011**, 29, 2598-607	2.2	407
118	EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. *European Journal of Cancer*, **2006**, 42, 1014-30	7.5	330
117	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. *Lancet, The*, **2017**, 390, 555-566	40	303
116	EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. *Blood*, **2011**, 118, 4024-35	2.2	295
115	European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. *European Journal of Cancer*, **2017**, 77, 57-74	7.5	240
114	Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. *Lancet Oncology, The*, **2018**, 19, 1192-1204	21.7	239
113	Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. *Journal of Clinical Oncology*, **2015**, 33, 3766-73	2.2	237
112	PLCG1 mutations in cutaneous T-cell lymphomas. *Blood*, **2014**, 123, 2034-43	2.2	150
111	Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. *Cancer Cell*, **2009**, 16, 103-14	24.3	146
110	TCR-δ expression in primary cutaneous T-cell lymphomas. *American Journal of Surgical Pathology*, **2013**, 37, 375-84	6.7	100
109	Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. *Haematologica*, **2010**, 95, 613-21	6.6	83
108	Whole-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine. *Nature*, **2017**, 546, 676-680	50.4	81
107	p16(INK4a) gene alterations are frequent in lesions of mycosis fungoides. *American Journal of Pathology*, **2000**, 156, 1565-72	5.8	77
106	Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and mutation. *Journal of Experimental Medicine*, **2019**, 216, 1061-1070	16.6	67
105	RAB7 controls melanoma progression by exploiting a lineage-specific wiring of the endolysosomal pathway. *Cancer Cell*, **2014**, 26, 61-76	24.3	66
104	MicroRNA expression profiling and DNA methylation signature for deregulated microRNA in cutaneous T-cell lymphoma. *Journal of Investigative Dermatology*, **2015**, 135, 1128-1137	4.3	63

103	Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. *European Journal of Cancer*, **2018**, 93, 47-56	7.5	61
102	Oligonucleotide array-CGH identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides. *Journal of Investigative Dermatology*, **2010**, 130, 1126-35	4.3	60
101	Shared Oncogenic Pathways Implicated in Both Virus-Positive and UV-Induced Merkel Cell Carcinomas. *Journal of Investigative Dermatology*, **2017**, 137, 197-206	4.3	55
100	Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients. *Journal of the American Academy of Dermatology*, **2013**, 69, 357-65	4.5	52
99	Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma. *British Journal of Dermatology*, **2012**, 167, 174-9	4	49
98	NIK controls classical and alternative NF-κB activation and is necessary for the survival of human T-cell lymphoma cells. *Clinical Cancer Research*, **2013**, 19, 2319-30	12.9	46
97	Lupus-like reaction to interferon at the injection site: report of five cases. *Journal of Cutaneous Pathology*, **2007**, 34 Suppl 1, 18-21	1.7	46
96	Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome. *British Journal of Dermatology* , **2016**, 175, 80-8	4	45
95	p16(INK4a) is selectively silenced in the tumoral progression of mycosis fungoides. *Laboratory Investigation*, **2002**, 82, 123-32	5.9	44
94	Alpha-1-antitrypsin deficiency panniculitis. *Dermatologic Clinics*, **2008**, 26, 447-51, vi	4.2	39
93	Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma. *Haematologica*, **2015**, 100, e450-3	6.6	38
92	Intra- and Inter-Tumoral Homogeneity of BRAF(V600E) Mutations in Melanoma Tumors. *Journal of Investigative Dermatology*, **2015**, 135, 3078-3085	4.3	37
91	Subcutaneous panniculitis-like T-cell lymphoma: Clinical features, therapeutic approach, and outcome in a case series of 16 patients. *Journal of the American Academy of Dermatology*, **2018**, 79, 892-898	4.5	32
90	p62/SQSTM1 Fuels Melanoma Progression by Opposing mRNA Decay of a Selective Set of Pro-metastatic Factors. *Cancer Cell*, **2019**, 35, 46-63.e10	24.3	30
89	Lineage-specific roles of the cytoplasmic polyadenylation factor CPEB4 in the regulation of melanoma drivers. *Nature Communications*, **2016**, 7, 13418	17.4	28
88	The Circulating Transcriptome as a Source of Biomarkers for Melanoma. *Cancers*, **2019**, 11,	6.6	28
87	Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. *Haematologica*, **2013**, 98, 57-64	6.6	25
86	The broad spectrum of dermatological manifestations in COVID-19: clinical and histopathological features learned from a series of 34 cases. *Journal of the European Academy of Dermatology and Venereology*, **2020**, 34, e574-e576	4.6	24

85	First-line treatment in lymphomatoid papulosis: a retrospective multicentre study. *Clinical and Experimental Dermatology*, **2018**, 43, 137-143	1.8	18
84	Síndrome linfoproliferativo CD30+ cutáneo primario. *Actas Dermo-sifiliográficas*, **2010**, 101, 119-128	0.5	18
83	DEK oncogene is overexpressed during melanoma progression. *Pigment Cell and Melanoma Research*, **2017**, 30, 194-202	4.5	17
82	Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-ΒB and nuclear factor of activated T cells pathways. *British Journal of Dermatology*, **2020**, 182, 147-155	4	17
81	Clinicopathologic and immunohistochemical studies on lichen amyloidosis and macular amyloidosis. *Archives of Dermatology*, **1994**, 130, 1559-60		17
80	PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases. *PLoS ONE*, **2014**, 9, e112148	3.7	16
79	Lupus like lesions in a patient with X-linked chronic granulomatous disease and recombinant X chromosome. *Dermatology*, **1997**, 195, 280-3	4.4	16
78	MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma. *Modern Pathology*, **2013**, 26, 171-81	9.8	15
77	Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways. *British Journal of Dermatology*, **2009**, 160, 92-102	4	15
76	Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: A case report. *Dermatologic Therapy*, **2019**, 32, e12829	2.2	14
75	Collagenase nanocapsules: An approach to fibrosis treatment. *Acta Biomaterialia*, **2018**, 74, 430-438	10.8	12
74	Primary cutaneous CD30+ anaplastic large-cell lymphomas show a heterogeneous genomic profile: an oligonucleotide arrayCGH approach. *Journal of Investigative Dermatology*, **2011**, 131, 269-71	4.3	12
73	Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state. *Nature Medicine*, **2020**, 26, 1865-1877	50.5	12
72	Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. *European Journal of Cancer*, **2020**, 133, 120-130	7.5	11
71	Systems analysis identifies melanoma-enriched pro-oncogenic networks controlled by the RNA binding protein CELF1. *Nature Communications*, **2017**, 8, 2249	17.4	11
70	Aprepitant improves refractory pruritus in primary cutaneous T-cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas. *British Journal of Dermatology*, **2018**, 178, e273-e274	4	11
69	Phacomatosis pigmentokeratotica: a case of HRAS mosaicism causing rhabdomyosarcoma. *British Journal of Dermatology*, **2018**, 179, 1163-1167	4	10
68	The First Year of the AEVD Primary Cutaneous Lymphoma Registry. *Actas Dermo-sifiliográficas*, **2018**, 109, 610-616	0.5	7

67	Developments in the understanding of blood involvement and stage in mycosis fungoides/Sezary syndrome. *European Journal of Cancer*, **2018**, 101, 278-280	7.5	7
66	Lack of Systemic Absorption of Topical Mechlorethamine Gel in Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma. *Journal of Investigative Dermatology*, **2021**, 141, 1601-1604.e2	4.3	7
65	Injection-site reaction to ixekizumab histologically mimicking lupus tumidus: Report of two cases. *Indian Journal of Dermatology, Venereology and Leprology*, **2018**, 84, 610-613	0.8	6
64	Response to brentuximab vedotin versus physician choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. *European Journal of Cancer*, **2021**, 148, 411-421	7.5	6
63	The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma. *British Journal of Haematology*, **2021**, 192, 683-696	4.5	6
62	Association of APOA5 and APOC3 Genetic Polymorphisms With Severity of Hypertriglyceridemia in Patients With Cutaneous T-Cell Lymphoma Treated With Bexarotene. *JAMA Dermatology*, **2018**, 154, 1424-1431	5.1	6
61	Alternaria infectoria skin infection in a renal transplant recipient: an emerging phaeohyphomycosis of occidental countries?. *International Journal of Dermatology*, **2017**, 56, e153-e155	1.7	5
60	Lipoatrophy associated with interferon alfa adjuvant therapy for melanoma. *Archives of Dermatology*, **2009**, 145, 98-9		5
59	Cutaneous macular amyloidosis associated with multiple endocrine neoplasia 2A. *Clinical and Experimental Dermatology*, **1996**, 21, 313-4	1.8	5
58	The new Cutaneous Lymphoma International Prognostic index (CLIPi) for early mycosis fungoides failed to identify prognostic groups in a cohort of Spanish patients. *British Journal of Dermatology*, **2016**, 175, 794-6	4	5
57	Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician choice in cutaneous T-cell lymphoma: final data. *Blood Advances*, **2021**, 5, 5098-5106	7.8	5
56	Rituximab in the treatment of primary cutaneous B-cell lymphoma: a review. *Actas Dermo-sifiliográficas*, **2014**, 105, 438-45	0.5	4
55	Lymphomatoid papulosis: a study of 18 cases*. *Journal of the European Academy of Dermatology and Venereology*, **1992**, 1, 205-216	4.6	4
54	Primary cutaneous peripheral T-cell lymphoma, not otherwise specified: results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico-pathological and prognostic features. *Journal of the European*	4.6	4
53	Prognostic factors in patients with primary cutaneous anaplastic large cell lymphoma: a multicentric, retrospective analysis of the Spanish Group of Cutaneous Lymphoma. *Journal of the European Academy of Dermatology and Venereology*, **2020**, 34, 762-768	4.6	4
52	Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study. *British Journal of Dermatology*, **2021**, 184, 524-531	4	4
51	Refractory pityriasis rubra pilaris with good response after treatment with ustekinumab. *JDDG - Journal of the German Society of Dermatology*, **2018**, 16, 1022-1025	1.2	4
50	Linear immunoglobulin A dermatosis mimicking toxic epidermal necrolysis: a case report of etanercept treatment. *British Journal of Dermatology*, **2018**, 178, 786-789	4	3

49	Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or vorinostat: A MAVORIC post-hoc analysis.. *Journal of Clinical Oncology* , **2019**, 37, 7539-7539	2.2	3
48	Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures. *Oncotarget*, **2015**, 6, 25452-65	3.3	3
47	Mycosis Fungoides and Sézary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy. *Cancers*, **2021**, 13,	6.6	3
46	Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IA-IIA Mycosis Fungoides. *Dermatology*, **2021**, 1-11	4.4	3
45	TIME TO NEXT TREATMENT IN PATIENTS WITH PREVIOUSLY TREATED CUTANEOUS T-CELL LYMPHOMA (CTCL) RECEIVING MOGAMULIZUMAB OR VORINOSTAT: A POST-HOC ANALYSIS OF THE MAVORIC STUDY. *Hematological Oncology*, **2019**, 37, 285-286	1.3	3
44	Real-world experience of using mogamulizumab in relapsed/refractory mycosis fungoides/Sézary syndrome. *British Journal of Dermatology*, **2021**, 184, 978-981	4	3
43	AraC-Ohren - durch Medikamente ausgelöst oder Manifestation einer neutrophilen Dermatose?. *JDDG - Journal of the German Society of Dermatology*, **2018**, 16, 213-215	1.2	2
42	Aprepitant did not modify global disease activity in cutaneous T-cell lymphomas. *British Journal of Dermatology*, **2018**, 178, 1222-1223	4	2
41	MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma. *Modern Pathology*, **2013**, 26, 617	9.8	2
40	Posible implicación de las alteraciones moleculares de la vía de TNF en la tumorigénesis de la micosis fungoide. Descripción de un posible chip de diagnóstico molecular en micosis fungoide. *Actas Dermo-sifiliográficas*, **2004**, 95, 86-96	0.5	2
39	Is mycosis fungoides associated with HTLV-I?. *Vox Sanguinis*, **1995**, 69, 84	3.1	2
38	Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study. *Blood*, **2019**, 134, 5300-5300	2.2	2
37	Leonine Facies, Flushing, and Systemic Symptoms. *JAMA Dermatology*, **2017**, 153, 925-926	5.1	1
36	Widespread biphasic amyloidosis related to ipilimumab treatment for metastatic melanoma. *International Journal of Dermatology*, **2017**, 56, e189-e191	1.7	1
35	Ara-C ears: an actual drug-induced reaction or a distinctive manifestation of a neutrophilic dermatosis?. *JDDG - Journal of the German Society of Dermatology*, **2018**, 16, 214-216	1.2	1
34	Rituximab in the Treatment of Primary Cutaneous B-Cell Lymphoma: A Review. *Actas Dermo-sifiliográficas*, **2014**, 105, 438-445	0.5	1
33	Hemophagocytic syndrome as a complication in a patient with Sézary syndrome. *International Journal of Dermatology*, **2013**, 52, 733-4	1.7	1
32	Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011.. *Journal of Clinical Oncology*, **2012**, 30, 8076-8076	2.2	1

31	Is cyclosporine a good option for the treatment of subcutaneous panniculitis-like T-cell lymphoma associated with hemophagocytic syndrome?. *Indian Journal of Dermatology, Venereology and Leprology*, **2019**, 85, 656-659	0.8	1
30	Systemic rituximab for the treatment of the indolent forms of primary cutaneous B-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry. *Journal of the American Academy of Dermatology*, **2020**, 83, 1535-1538	4.5	1
29	Dermoscopy and reflectance confocal microscopy features of acquired lymphangiectasias following surgery and radiotherapy of breast cancer. *International Journal of Dermatology*, **2021**, 60, e429-e431	1.7	1
28	Therapierefraktäre Pityriasis rubra pilaris mit gutem Ansprechen auf Ustekinumab. *JDDG - Journal of the German Society of Dermatology*, **2018**, 16, 1022-1025	1.2	1
27	Activity and safety of topical pimecrolimus in patients with early stage mycosis fungoides (PimTo-MF): a single-arm, multicentre, phase 2 trial. *Lancet Haematology,the*, **2022**, 9, e425-e433	14.6	1
26	Drug reaction with eosinophilia and systemic symptoms in a 10-year-old boy sparing lichen planus lesions: an example of reverse isotopic response.. *Journal of the European Academy of Dermatology and Venereology*, **2022**,	4.6	0
25	Health-related quality of life effect of mogamulizumab by patient blood involvement. *European Journal of Cancer*, **2021**, 156 Suppl 1, S65-S66	7.5	0
24	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.. *Journal of Clinical Oncology*, **2021**, 39, 9500-9500	2.2	0
23	Romidepsin-induced sterile folliculitis in a patient with Sézary syndrome. *International Journal of Dermatology*, **2021**,	1.7	0
22	Patients with primary cutaneous lymphoma are at risk for severe COVID-19. Data from the Spanish Primary Cutaneous Lymphoma Registry. *Journal of the European Academy of Dermatology and Venereology*, **2021**, 35, e624-e626	4.6	0
21	Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity. *British Journal of Dermatology*, **2021**, 185, 1035-1044	4	0
20	Condyloma-like lesions in a young woman: Not always synonym of genital warts. *European Journal of Obstetrics, Gynecology and Reproductive Biology*, **2017**, 213, 142-143	2.4	
19	Rapidly-developing alopecic nodules in a young man. *International Journal of Dermatology*, **2020**, 59, 1219-1221	1.7	
18	Cost of early-stage mycosis fungoides treatments in Spain. *ClinicoEconomics and Outcomes Research* , **2020**, 12, 91-105	1.7	
17	PIK3CA-related overgrowth spectrum: concurrence of multiple anomalies in one patient. *JDDG - Journal of the German Society of Dermatology*, **2018**, 16, 603-605	1.2	
16	PIK3CA-assoziiertes Überwuchsspektrum: gleichzeitiges Auftreten mehrerer Anomalien bei einem Patienten. *JDDG - Journal of the German Society of Dermatology*, **2018**, 16, 603-605	1.2	
15	The First Year of the AEVD Primary Cutaneous Lymphoma Registry. *Actas Dermo-sifiliográficas*, **2018**, 109, 610-616	0.5	
14	Fotofílesis. *Actas Dermo-sifiliográficas*, **2009**, 100, 443-444	0.5	

13	Photopheresis. *Actas Dermo-sifiliográficas*, **2009**, 100, 443-444	0.5
12	Two cases of generalized eruptive lentiginosis in cutaneous T-cell lymphoma following mogamulizumab treatment.. *International Journal of Dermatology*, **2022**,	1.7
11	Live imaging of neolymphangiogenesis identifies acute antimetastatic roles of dsRNA mimics. *EMBO Molecular Medicine*, **2021**, 13, e12924	12
10	Progression-Free Survival and Overall Survival Among a Patient Cohort of Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom. *Blood*, **2019**, 134, 5879-5879	2.2
9	The EORTC Cutaneous T-Cell Lymphoma (CTCL) Platform. *Blood*, **2010**, 116, 4896-4896	2.2
8	PIM Kinases Inhibition, a Rational Strategy in Peripheral T-Cell Lymphomas,. *Blood*, **2011**, 118, 3494-3494	2.2
7	PI3K Inhibition As a Potential Therapeutic Strategy in Peripheral T-Cell Lymphomas,. *Blood*, **2011**, 118, 3493-3493	2.2
6	Mutations in PLCG1 Is a Frequent Event in Cutaneous T-Cell Lymphomas. *Blood*, **2012**, 120, 300-300	2.2
5	Systemic Treatment of Primary Cutaneous Lymphomas **2014**, 445-460	
4	Millimeter-sized facial papules in a patient receiving chronic hemodialysis. *JDDG - Journal of the German Society of Dermatology*, **2020**, 18, 1515-1517	1.2
3	The time for new biomarkers in mycosis fungoides/Sézary syndrome is here. *British Journal of Dermatology*, **2021**, 185, 250-251	4
2	Targeting KIR3DL2 in primary cutaneous anaplastic large cell lymphomas. *British Journal of Dermatology*, **2016**, 175, 246-7	4
1	Primary cutaneous anaplastic large-cell lymphoma successfully treated with intralesional brentuximab vedotin: a case report. *International Journal of Dermatology*, **2021**,	1.7